LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Posterior reversible encephalopathy and Guillain-Barré syndrome: which came first, the chicken or the egg? A review of literature.

    Storti, Benedetta / Vedovello, Marcella / Riva, Riccardo / Agazzi, Emanuela / Censori, Bruno / Manara, Ornella / Sessa, Maria / Rottoli, Maria Rosa

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

    2020  Volume 41, Issue 12, Page(s) 3663–3666

    Abstract: Posterior reversible encephalopathy (PRES) is a rare occurrence in patients with Guillain-Barré syndrome (GBS) with only nine adult cases reported to date. We conducted a review of the literature and compared previous cases with a novel case admitted to ... ...

    Abstract Posterior reversible encephalopathy (PRES) is a rare occurrence in patients with Guillain-Barré syndrome (GBS) with only nine adult cases reported to date. We conducted a review of the literature and compared previous cases with a novel case admitted to our clinic. In light of the timing of the symptoms, it is assumable that arterial hypertension can develop acutely during a phase of GBS-related autonomic dysfunction and subsequently precipitates PRES. According to this, dysautonomia caused by GBS could precede motor weakness; thus, PRES in the absence of any strong alternative etiology may suggest an underlying GBS.
    MeSH term(s) Ambulatory Care Facilities ; Brain Diseases ; Guillain-Barre Syndrome/complications ; Guillain-Barre Syndrome/diagnosis ; Humans ; Hypertension ; Posterior Leukoencephalopathy Syndrome
    Language English
    Publishing date 2020-06-06
    Publishing country Italy
    Document type Journal Article ; Review
    ZDB-ID 2016546-8
    ISSN 1590-3478 ; 1590-1874
    ISSN (online) 1590-3478
    ISSN 1590-1874
    DOI 10.1007/s10072-020-04496-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1877: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Fostering adherence to injectable disease-modifying therapies in multiple sclerosis.

    Lugaresi, Alessandra / Rottoli, Maria Rosa / Patti, Francesco

    Expert review of neurotherapeutics

    2014  Volume 14, Issue 9, Page(s) 1029–1042

    Abstract: Multiple sclerosis requires long-term management, often with disease-modifying therapies. Poor medication adherence, especially to injectables, can increase relapse and hospitalisation rates and consume healthcare resources. We discuss adherence ... ...

    Abstract Multiple sclerosis requires long-term management, often with disease-modifying therapies. Poor medication adherence, especially to injectables, can increase relapse and hospitalisation rates and consume healthcare resources. We discuss adherence definitions and terminology and its prevalence in multiple sclerosis (MS). Typical causes of poor adherence in patients with MS include: insufficient efficacy or tolerability, concurrent disorders, and consequences of MS (e.g., forgetfulness, depression, fatigue and poor motor skills). Ways to improve adherence rates are reviewed, focusing on interdisciplinary healthcare teams, good communication between healthcare workers and patients (and their families), ongoing support and digital tools to promote adherence. We consider open communication and continuing education to be key, and that MS nurses have a pivotal role in ensuring patients' adherence to MS medicines.
    MeSH term(s) Adjuvants, Immunologic/administration & dosage ; Drug Delivery Systems ; Humans ; Interferon beta-1b ; Interferon-beta/administration & dosage ; Multiple Sclerosis/drug therapy ; Multiple Sclerosis/epidemiology ; Multiple Sclerosis/psychology ; Patient Compliance
    Chemical Substances Adjuvants, Immunologic ; Interferon beta-1b (145155-23-3) ; Interferon-beta (77238-31-4)
    Language English
    Publishing date 2014-09
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2112534-X
    ISSN 1744-8360 ; 1473-7175
    ISSN (online) 1744-8360
    ISSN 1473-7175
    DOI 10.1586/14737175.2014.945523
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6155: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: EEG reactivity predicts recovery of consciousness in patients with acute brain injury and signs of intracranial hypertension.

    Longhi, Luca / Cavalleri, Gaia / Ferri, Francesco / Lorini, Luca / Zangari, Rosalia / Rottoli, Maria Rosa / Frigeni, Barbara

    Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology

    2019  Volume 130, Issue 10, Page(s) 1741–1742

    MeSH term(s) Adult ; Aged ; Brain Injuries/diagnosis ; Brain Injuries/physiopathology ; Consciousness/physiology ; Consciousness Disorders/diagnosis ; Consciousness Disorders/physiopathology ; Electroencephalography/methods ; Electroencephalography/trends ; Female ; Humans ; Intracranial Hypertension/diagnosis ; Intracranial Hypertension/physiopathology ; Male ; Middle Aged ; Predictive Value of Tests ; Recovery of Function/physiology
    Language English
    Publishing date 2019-07-26
    Publishing country Netherlands
    Document type Letter
    ZDB-ID 1463630-x
    ISSN 1872-8952 ; 0921-884X ; 1388-2457
    ISSN (online) 1872-8952
    ISSN 0921-884X ; 1388-2457
    DOI 10.1016/j.clinph.2019.07.015
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui II Zs.140: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: MxA mRNA quantification and disability progression in interferon beta-treated multiple sclerosis patients.

    Serana, Federico / Imberti, Luisa / Amato, Maria Pia / Comi, Giancarlo / Gasperini, Claudio / Ghezzi, Angelo / Martinelli, Vittorio / Provinciali, Leandro / Rottoli, Maria Rosa / Sotgiu, Stefano / Stecchi, Sergio / Vecchio, Michele / Zaffaroni, Mauro / Cordioli, Cinzia / Capra, Ruggero

    PloS one

    2014  Volume 9, Issue 4, Page(s) e94794

    Abstract: Even though anti-interferon beta (IFNβ) antibodies are the main determinants of IFNβ bioactivity loss and Myxovirus-resistance protein A (MxA) is the most established marker of IFNβ biological activity in IFNβ-treated multiple sclerosis patients, their ... ...

    Abstract Even though anti-interferon beta (IFNβ) antibodies are the main determinants of IFNβ bioactivity loss and Myxovirus-resistance protein A (MxA) is the most established marker of IFNβ biological activity in IFNβ-treated multiple sclerosis patients, their usefulness in the routine clinical practice is still debated. Therefore, 118 multiple sclerosis patients naïve for treatment were enrolled for a 3-year longitudinal observational study mimicking the conditions of a real-world setting. In order to evaluate the kinetics of bioactivity loss in blood samples obtained every 6 months after therapy initiation, MxA and interferon receptor isoform/subunit mRNA were quantified by real-time PCR, anti-IFNβ binding antibodies were detected by radioimmunoprecipitation, and neutralizing antibodies by cytopathic effect inhibition assay. Clinical measures of disease activity and disability progression were also obtained at all time points. We found that, at the individual-patient level, the response to IFNβ therapy was extremely heterogeneous, including patients with stable or transitory, early or late loss of IFNβ bioactivity, and patients with samples lacking MxA mRNA induction in spite of absence of antibodies. No interferon receptor isoform alterations that could explain these findings were found. At the group level, none of these biological features correlated with the measures of clinical disease activity or progression. However, when MxA mRNA was evaluated not at the single time point as a dichotomic marker (induced vs. non-induced), but as the mean of its values measured over the 6-to-24 month period, the increasing average MxA predicted a decreasing risk of short-term disability progression, independently from the presence of relapses. Therefore, a more bioactive treatment, even if unable to suppress relapses, reduces their severity by an amount that is proportional to MxA levels. Together with its feasibility in the routine laboratory setting, these data warrant the quantification of MxA mRNA as a primary tool for a routine monitoring of IFNβ therapy.
    MeSH term(s) Adolescent ; Adult ; Antibodies, Neutralizing ; Biomarkers/metabolism ; Disability Evaluation ; Disease Progression ; Female ; Humans ; Interferon-beta/therapeutic use ; Kinetics ; Male ; Middle Aged ; Multiple Sclerosis/drug therapy ; Multiple Sclerosis/genetics ; Myxovirus Resistance Proteins/genetics ; Myxovirus Resistance Proteins/metabolism ; Patient Dropouts ; Protein Isoforms/genetics ; Protein Isoforms/metabolism ; Protein Subunits/genetics ; Protein Subunits/metabolism ; RNA, Messenger/genetics ; RNA, Messenger/metabolism ; Receptor, Interferon alpha-beta/metabolism ; Young Adult
    Chemical Substances Antibodies, Neutralizing ; Biomarkers ; Myxovirus Resistance Proteins ; Protein Isoforms ; Protein Subunits ; RNA, Messenger ; Receptor, Interferon alpha-beta (156986-95-7) ; Interferon-beta (77238-31-4)
    Language English
    Publishing date 2014-04-14
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 1932-6203
    ISSN (online) 1932-6203
    DOI 10.1371/journal.pone.0094794
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top